Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
December 04, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc
Legacy Housing Corporation Reports Second Quarter 2022 Financial Results and Regains Compliance with SEC Filings
September 23, 2022 15:37 ET
|
Legacy Housing Corporation
BEDFORD, Texas, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (the "Company” or “Legacy", NASDAQ: LEGH) today announced its financial results for the Second quarter ended June 30,...
Mobiquity Technologies Reports Second Quarter 2022 Financial Results and Business Update
August 19, 2022 08:30 ET
|
Mobiquity Technologies, Inc.
Q2 2022 versus Q2 2021 revenue growth of 273%6-months 2022 versus 6-months 2021 revenue growth of 201%Loss from Operations decreased by 53% Q2 2022 versus Q2 2021 and by 20% for the 6-months 2022...
Progressive Care to Host Conference Call on Third Quarter 2018 Financial Results and Business Update on November 14th
November 09, 2018 08:00 ET
|
Progressive Care, Inc.
MIAMI, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, is pleased to announce that the Company has scheduled an...
Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
May 08, 2018 06:00 ET
|
Cellular Biomedicine Group Inc.
China Food and Drug Administration Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T Therapy Targeting NHL and ALLPositive 48-Week Phase I Clinical Data of...
Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Operational Highlights
November 09, 2017 08:30 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical company engaged...
AXIM Biotechnologies Reports Second Quarter 2017 Results
August 22, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter...
Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights
August 08, 2017 16:31 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business Highlights
May 08, 2017 16:01 ET
|
Cellular Biomedicine Group Inc.
Commenced Phase I Trial (CALL-1) for C-CAR011 in adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (ALL) in ChinaStrategic partnership with GE Healthcare Life Sciences...
UPDATE -- Cellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business Highlights
August 09, 2016 09:36 ET
|
Cellular Biomedicine Group Inc.
- Ended Second Quarter with $47.5 million in Cash - SHANGHAI, China and CUPERTINO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the...